BioSpace News Archive

Indaptus Therapeutics, Inc. today announced financial results for the first quarter ended March 31, 2024, and provided a corporate update.

Belite Bio, Inc today announced that it will host a webcast on Tuesday, May 14, 2024, at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a business update for the first quarter ended March 31, 2024.

Recce Pharmaceuticals Ltd. today announced the China National Intellectual Property Administration has formally granted Recce a new family two patent, “ Copolymer and Method for Treatment of Bacterial Infection , ” for its anti-infectives, with expiry in 2035.

IMUNON, Inc. today announced the appointment of Stacy R. Lindborg, Ph.D. as President and Chief Executive Officer, effective May 13, 2024.

Spero Therapeutics, Inc. today announced that it will report its first quarter 2024 financial results and provide an update on its business and pipeline on Wednesday, May 15, after the market close.

AbbVie announced that Health Canada has approved QULIPTA for the prevention of migraine in adults who have at least four migraine days per month.

Premier, Inc. is excited to announce a strategic partnership with AstraZeneca called Uncover CKD - Care Collective aiming to identify patients with undiagnosed clinical chronic kidney disease ; raise awareness of undiagnosed CKD among healthcare providers; and inform U.S. health systems that want to improve or develop and implement their strategies for CKD diagnosis, treatment and management.

STRATA Skin Sciences, Inc. announces that it will report first quarter 2024 financial results on Wednesday, May 15, 2024 after the market close.

Xylyx Bio today announced entry into an exclusive license agreement with Vanderbilt University for the rights to a xenogeneic cross-circulation platform that restores damaged donor organs to transplant condition.

InflaRx N.V. announced financial results for the three months ended March 31, 2024, and provided an operating update.